First Time Loading...

Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 0.6998 USD -2.08%
Updated: Apr 26, 2024

Operating Margin
Atara Biotherapeutics Inc

-3 141%
Current
-2 649%
Average
-8.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 141%
=
Operating Profit
-269.3m
/
Revenue
8.6m

Operating Margin Across Competitors

Operating Margin Comparison
Atara Biotherapeutics Inc Competitors

Country Company Market Cap Operating
Margin
US
Atara Biotherapeutics Inc
NASDAQ:ATRA
74.5m USD
-3 141%
US
Abbvie Inc
NYSE:ABBV
286.7B USD
30%
US
Amgen Inc
NASDAQ:AMGN
144.8B USD
29%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.5B USD
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.9B USD
32%
AU
CSL Ltd
ASX:CSL
132B AUD
26%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
34%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Moderna Inc
NASDAQ:MRNA
41.2B USD
-62%
US
Biogen Inc
NASDAQ:BIIB
29.9B USD
21%
KR
Celltrion Inc
KRX:068270
36.6T KRW
30%
Atara Biotherapeutics Inc
NASDAQ:ATRA
Country US
Market Cap 74.5m USD
Operating Margin
-3 141%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 286.7B USD
Operating Margin
30%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 144.8B USD
Operating Margin
29%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 102.5B USD
Operating Margin
39%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 96.9B USD
Operating Margin
32%
CSL Ltd
ASX:CSL
Country AU
Market Cap 132B AUD
Operating Margin
26%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 81.6B USD
Operating Margin
34%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 41.2B USD
Operating Margin
-62%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 29.9B USD
Operating Margin
21%
Celltrion Inc
KRX:068270
Country KR
Market Cap 36.6T KRW
Operating Margin
30%

Profitability Report

View the profitability report to see the full profitability analysis for Atara Biotherapeutics Inc.

Full Profitability Report

See Also

Summary
ATRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATRA stock valuation using valuation multiples.
Wall Street Estimates
ATRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 141%
=
Operating Profit
-269.3m
/
Revenue
8.6m
What is the Operating Margin of Atara Biotherapeutics Inc?

Based on Atara Biotherapeutics Inc's most recent financial statements, the company has Operating Margin of -3 141%.

ALPHA SPREAD
Join more than 131,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.